How to read: Every bubble is one Indian etoposide exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Etoposide report covers
KEY TAKEAWAYEvery figure in this report is grounded in real commercial etoposide trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian etoposide suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Etoposide India trade report
P
Product scope
Etoposide
All variants merged — branded and generic formulations of etoposide
T
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
S
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
G
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
C
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
R
Shipments analysed
258
Every commercial etoposide trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY2025-Q4 followed a mixed: Oct $1.2M, Nov $625.1K, Dec $171.5K. Shipment counts were mixed across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$1.2M
Oct USD
84 shipments
2
$625.1K
Nov USD
-45.8% MoM
3
$171.5K
Dec USD
-72.6% MoM
4
Mixed
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 45.8% in USD but shipment count kept climbing.
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $1.2M, making it the strongest month by value.
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: INTAS PHARMACEUTICALS LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import etoposide from India, how much they buy, and who supplies each market
KEY TAKEAWAYPoland absorbs 27.4% of India’s 2025-Q4 etoposide trade ($534.8K). Beyond the top 10 destinations, 54 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Africa has 16 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 54 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much etoposide India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$32K
1.6% of trade
15 countries · 48 shipments
Europe
$1.7M
86.5% of trade
12 countries · 151 shipments
Americas
$182K
9.3% of trade
10 countries · 19 shipments
Africa
$51K
2.6% of trade
16 countries · 39 shipments
Oceania
$0
0.0% of trade
1 countries · 1 shipments
Fig 4.1 Poland is the #1 corridor ($535K) — 30 flow arcs from India radiate across 5 continents.
How to read: The world map shows every country colored by how much Indian etoposide it receives (light = low, dark = high). Orange arcs radiate from India to the top 30 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
#
Destination
Total USD
Ships
#1 Indian supplier
USD
#2 Indian supplier
USD
#3 Indian supplier
USD
1
Poland
$535K
29
INTAS PHARMACEUTICALS LTD
$534K
VAMA LIFECARE PVT LTD
$398
—
—
2
Greece
$399K
36
INTAS PHARMACEUTICALS LTD
$399K
—
—
—
—
3
Netherlands
$322K
31
INTAS PHARMACEUTICALS LTD
$322K
—
—
—
—
4
France
$185K
3
MYLAN LABORATORIES LTD
$140K
INTAS PHARMACEUTICALS LTD
$44K
—
—
5
Russia
$96K
3
RUS MED EXPORTS PVT LTD
$94K
GENETEC LIFESCIENCES
$2K
UNITED BIOTECH PVT LTD
$700
6
United States
$79K
1
INTAS PHARMACEUTICALS LTD
$79K
—
—
—
—
7
Mexico
$75K
10
INTAS PHARMACEUTICALS LTD
$72K
MYGENIC HEALTHCARE PVT LTD
$3K
ATLAS ENTERPRISES
$157
8
Germany
$68K
1
FRESENIUS KABI ONCOLOGY LTD
$68K
—
—
—
—
9
South Africa
$35K
3
FRESENIUS KABI ONCOLOGY LTD
$35K
VENUS REMEDIES LTD
$168
—
—
10
United Kingdom
$33K
2
INTAS PHARMACEUTICALS LTD
$33K
—
—
—
—
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 1.6% of USD — but Poland is the single largest market.
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
27.4%
#1 country share
Poland alone
78.8%
Top 5 share
5 of 54 countries
97.5%
Top 15 share
Long tail of 39 countries = 2.5%
HHI 1610
Destination HHI
Moderately concentrated
54
Countries served
Global pharma reach from India
16
Africa countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
62 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAYINTAS PHARMACEUTICALS LTD ($1.5M, 77.4% share) and MYLAN LABORATORIES LTD ($140.3K) together control 84.5% of India’s 2025-Q4 etoposide trade. The top 5 suppliers hold 96.4%. 62 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian etoposide suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 INTAS PHARMACEUTICALS LTD leads by $1.4M over MYLAN LABORATORIES LTD — top 20 Indian exporters ranked by trade value
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: M.K.PHARMA is #20 by value but #8 by volume.
Fig 5.2 INTAS PHARMACEUTICALS LTD also leads by shipment count (143) but ranking shifts for volume-heavy players
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: M.K.PHARMA moves from #8 by volume to #20 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 62 etoposide suppliers split into strategic segments
KEY TAKEAWAY16 suppliers (25%) generate 99.1% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 INTAS PHARMACEUTICALS LTD and MYLAN LABORATORIES LTD sit in the leaders zone — high volume AND high value.
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 99.1% of USD — classic concentration.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 5 destinations and up to 5 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
How to read: Left = Indian supplier. Middle = destination countries (ordered by USD). Right = importers within each country. Ribbon thickness = USD value; color = country. Every node labeled with name + USD + ships. Showing top 4 destinations and up to 2 importers per destination.
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
57 importers across 54 countries — who is buying Indian etoposide and how much
KEY TAKEAWAYThe demand side is dramatically more fragmented than supply: the top 25 importers together hold only 40.8% of total USD. 96% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian etoposide. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 CSP P/O VIATRIS SA is the #1 importer at $140K (7.2%) — top 25 by trade value
How to read: Left semicircle = top 20 Indian suppliers; right = top 20 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian etoposide prices vary by supplier, country and dosage form
KEY TAKEAWAYEtoposide prices span 1801× ($0.012 → $21.62). The coefficient of variation is 0.89. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. UNITED BIOTECH PVTSourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. INTAS PHARMACEUTICALS LTDSourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. NEOPHAR PHARMACEUTICALS PVTSourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. RUS MED EXPORTSSourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAYExtreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Oct 2025
MYLAN LABORATORI…
France
Injection
2K
$140K
$75.13
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
United States
Injection
2K
$79K
$40.91
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
85
$2K
$21.62
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
391
$8K
$21.62
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
368
$8K
$21.36
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
85
$2K
$21.36
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
913
$19K
$20.27
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
85
$2K
$20.27
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
85
$2K
$20.22
Sterile formulation premium
Oct 2025
INTAS PHARMACEUT…
Netherlands
Injection
681
$14K
$20.22
Sterile formulation premium
↓ TOP 10 LOWEST USD/UNIT
Date
Exporter
Country
Dosage
Qty
USD
$/unit
Why
Dec 2025
AMRS HEALTHCARE …
Venezuela
Capsule
6K
$40.68
$0.0066
Dec 2025
RMPL PHARMA LLP
Turkey
Injection
600
$6.19
$0.010
Sterile formulation premium
Dec 2025
M T MADON EXPORTS
Somalia
Injection
750
$9.00
$0.012
Sterile formulation premium
Dec 2025
VENUS REMEDIES LTD
Colombia
Injection
8K
$96.71
$0.012
Sterile formulation premium
Dec 2025
ATLAS ENTERPRISES
Mexico
Injection
400
$6.83
$0.017
Sterile formulation premium
Dec 2025
SANSKRUTI PHARMA
Burkina Faso
Injection
200
$4.29
$0.021
Sterile formulation premium
Dec 2025
SR FARMALIFE PVT…
Burkina Faso
Injection
10
$0.224
$0.022
Sterile formulation premium
Dec 2025
RUTVA MEDICARE
Ghana
—
50
$1.14
$0.023
Small sample / trial shipment
Dec 2025
AL-ROYAL PHARMAC…
Egypt
Capsule
1K
$44.87
$0.039
Dec 2025
NARAYANA HRUDAYA…
Cayman Islands
Injection
21
$0.837
$0.040
Sterile formulation premium
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
Dosage form is the #1 price driver, not destination
Light cells = easy-entry markets for small suppliers
Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship etoposide, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAYEtoposide leaves India through 12+ ports. The top 5 (MUNDRA SEA, AHMEDABAD AIR, BANGALORE AIR) handle 95.1% of total USD. SEA moves 27% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 MUNDRA SEA handles $1.2M — top 12 Indian origin ports by trade value.
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
Route
Mode
Transit time
Notes
NHAVA SHEVA SEA (JNPT) → US East Coast
Sea
22–28 days
Via Suez; 2–3 transshipments typical
NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria)
Sea
18–24 days
Direct liner service available
MUMBAI AIR (SAHAR) → New York JFK
Air
3–5 days
Direct cargo; cold-chain available
MUNDRA SEA → Rotterdam
Sea
20–26 days
Via Suez; Hamburg also served
HYDERABAD AIR → London Heathrow
Air
2–4 days
Pharma-grade cargo corridor
CHENNAI SEA → Chittagong (Bangladesh)
Sea
7–12 days
Short-sea route; high frequency
RAXAUL → Birgunj (Nepal)
Road
1–2 days
Land border crossing
NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya)
Sea
14–20 days
Direct or via Colombo hub
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAYSEA dominates at 27% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
SEA
$1.2M
60.0% of USD · 27.1% of ships
AIR
$710K
36.4% of USD · 72.1% of ships
ICD
$71K
3.6% of USD · 0.8% of ships
Fig 8.3 The dominant corridor is MUNDRA SEA → Sea → Europe ($1.2M).
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAYMalta is the most concentrated destination (HHI 10000, 1 suppliers). United Arab Emirates is the most competitive (HHI 2772).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 Malta (HHI 10,000) is the most concentrated — United Arab Emirates (HHI 2,772) is the most competitive.
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 20 of 20 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
Buyer
Country
Sole supplier
USD
Ships
Risk
CSP P/O VIATRIS SA
France
MYLAN LABORATORI…
$140K
1
HIGH
LLC MANAS MED
Russia
RUS MED EXPORTS …
$94K
1
MEDIUM
ACCORD HEALTHCARE FR…
Netherlands
INTAS PHARMACEUT…
$84K
6
MEDIUM
AMERISOURCE HEALTH S…
United States
INTAS PHARMACEUT…
$79K
1
MEDIUM
ACCORD FARMA S.A. DE…
Mexico
INTAS PHARMACEUT…
$72K
2
MEDIUM
FRESENIUS KABI DEUTS…
Germany
FRESENIUS KABI O…
$68K
1
MEDIUM
BROCACEF NL:EU HUB
Netherlands
INTAS PHARMACEUT…
$44K
4
MEDIUM
BROCACEF NL : LOCAL
Netherlands
INTAS PHARMACEUT…
$43K
2
MEDIUM
Conclusion: 55 buyers depend on exactly one Indian supplier, representing $803K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
Buyer
Country
Suppliers
USD
Dominant
Resilience
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
Country
Tier
Lead
Price
Risk
Entry approach
Poland
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Greece
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Netherlands
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
France
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Russia
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
United States
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Mexico
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Germany
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
South Africa
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
United Kingdom
Tier 3 (emerging)
14–28 days (sea)
$1–$10/unit
LOW
First-mover advantage
Lithuania
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Chile
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Italy
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Malta
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
Pakistan
Tier 3 (emerging)
3–5 days (air)
$1–$10/unit
LOW
First-mover advantage
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 14 in Fragile Dependency (concentrated + shrinking).
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 15 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAYQuick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 15 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
ID
Action
Timing
Impact
A1
Pitch top single-source buyer in France
This Q
HIGH
A2
Offer alternative to top multi-source buyer
This Q
HIGH
A3
Audit Malta lock-ins (HHI 10000)
This Q
MED
A5
Enter Poland (2 suppliers)
This Q
HIGH
A6
Enter Greece (1 suppliers)
This Q
MED
A8
Build Greece distribution
6–12m
HIGH
A9
Bundle injection/infusion catalog for premium markets
6–12m
MED
B
FOR BUYERS
ID
Action
Timing
Impact
A4
Monitor rising exporters (climbers)
This Q
MED
A7
Register for Poland tenders
6–12m
HIGH
A10
Track quarterly HHI shifts across key destinations
This Q
LOW
A11
Map competitor buyer portfolios quarterly
This Q
MED
A12
Qualify second source for single-source buyers
This Q
MED
§9.4 Easy-entry markets — 15 countries with ≤5 Indian suppliers
#
Country
Region
Suppliers
Q4 USD
Growth
Barrier
Why this is easy
1
Poland
Other
2
$535K
-60.8%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
2
Greece
Other
1
$399K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
3
Netherlands
Other
1
$322K
-50.5%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
4
France
Other
2
$185K
-100%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
5
Russia
Other
3
$96K
-97.1%
LOW
Low competition (3 suppliers), accessible market
6
United States
Other
1
$79K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
7
United Arab Emirates
Other
4
$3K
+2876.9%
LOW
Growing 2877% with only 4 competitors
8
Mexico
Other
4
$75K
-95.9%
LOW
Low competition (4 suppliers), accessible market
9
Germany
Other
1
$68K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
10
South Africa
Africa
2
$35K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
11
United Kingdom
Other
1
$33K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
12
Lithuania
Other
2
$21K
0%
LOW
Only 2 Indian suppliers — near-monopoly, easy second-source entry
13
Chile
Other
1
$21K
0%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
14
Italy
Other
1
$16K
-100%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
15
Malta
Other
1
$10K
-95.7%
LOW
Only 1 Indian suppliers — near-monopoly, easy second-source entry
This report covers 258 2025-Q4 Etoposide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/etoposide
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAYThis section contains every one of the 258 2025-Q4 etoposide shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian etoposide shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
258
across all regions
TOTAL USD
$1.95M
2025-Q4 FOB value
UNITS
313.7K
tablets, capsules, etc.
SUPPLIERS
62
Indian exporters
BUYERS
57
global importers
COUNTRIES
54
destinations
§10.2 Regional breakdown
Africa
$51K
2.6%
16 ctry · 39 ships
Asia
$32K
1.6%
15 ctry · 48 ships
Europe
$1.69M
86.5%
12 ctry · 151 ships
Americas
$182K
9.3%
10 ctry · 19 ships
Oceania
$0.0000
0.0%
1 ctry · 1 ships
§10.3 Key insights from the data
🌍
Africa is the largest region at $51K (2.6%), spanning 16 countries.
🏢
62 Indian suppliers shipped to 57 buyers across 54 countries — average shipment value $8K.
📄
Top 0 markets: .
🔍
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
All 55 global etoposide importers — complete list ranked by USD
KEY TAKEAWAYThis directory lists every company that imported Indian etoposide in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
#
Buyer
Country
Ships
USD
Primary supplier
Dosage forms
1
CSP P/O VIATRIS SA
France
1
$140K
MYLAN LABORATORIES LTD
Injection
2
LLC MANAS MED
Russia
1
$94K
RUS MED EXPORTS PVT …
Injection
3
ACCORD HEALTHCARE FRANCE SAS
Netherlands
6
$84K
INTAS PHARMACEUTICAL…
Injection
4
AMERISOURCE HEALTH SERVICES
United States
1
$79K
INTAS PHARMACEUTICAL…
Injection
5
ACCORD FARMA S.A. DE C.V
Mexico
2
$72K
INTAS PHARMACEUTICAL…
Vaccine
6
FRESENIUS KABI DEUTSCHLAND GMBH
Germany
1
$68K
FRESENIUS KABI ONCOL…
Injection
7
BROCACEF NL:EU HUB
Netherlands
4
$44K
INTAS PHARMACEUTICAL…
Injection
8
BROCACEF NL : LOCAL
Netherlands
2
$43K
INTAS PHARMACEUTICAL…
Injection
9
ACCORD HEALTHCARE SINGLE MEMBER SA
Greece
21
$41K
INTAS PHARMACEUTICAL…
Injection
10
FRESENIUS KABI SOUTH AFRICA (PTY) L
South Africa
2
$35K
FRESENIUS KABI ONCOL…
Injection
11
BROCACEF NL : EU HUB
Netherlands
1
$27K
INTAS PHARMACEUTICAL…
12
SPECIALTY LAB SPA
Chile
1
$21K
ADMAC LIFESCIENCES
Injection
13
ACCORD HEALTHCARE ITALIA SRL
Italy
2
$16K
INTAS PHARMACEUTICAL…
Injection
14
P D T S A
Costa Rica
1
$7K
VENUS REMEDIES LTD
Injection
15
MEGA SUNSHINE COMPANY LTD
Myanmar
1
$4K
KHANDELWAL LABORATOR…
Capsule
16
ATCO PHARMA INTERNATIONAL PVT LTD
Pakistan
1
$4K
FRESENIUS KABI ONCOL…
Injection
17
R M S
Rwanda
1
$4K
VENUS REMEDIES LTD
Injection
18
SAK CAM PHARMA CO LTD
Cambodia
1
$3K
UNITED BIOTECH PVT LTD
Injection
19
CENTRALE D ACHATS DE MEDICAMENTS
Madagascar
1
$2K
ZUVIUS LIFESCIENCES …
Injection
20
AURORA LLC
Russia
1
$2K
GENETEC LIFESCIENCES
Injection
21
TO THE
Rwanda
1
$2K
PNT PHARMA
Tablet
22
AL-NOOR FOR DRUGS & MEDICAL APPLIAN
Yemen
4
$2K
J.A. UNITED EXPORTS …
Capsule, Injection
23
SIJAL PHARMA PVT LTD
Nepal
1
$1K
BETA DRUGS LTD
Capsule
24
LLC TIBBI JAHON
Tajikistan
3
$1K
M.K.PHARMA
Vial
25
VISION CARE INTERNATIONAL PVT LTD
Nepal
1
$1K
GETWELL PHARMA INDIA…
Injection
26
BEST INTERNATIONAL FZE
United Arab Emirates
4
$848.00
MEDEX PHARMACEUTICALS
Injection
27
ZMC EXPRESS CARGO FZCO
United Arab Emirates
3
$614.67
SEATRACK INTERNATION…
Capsule, Injection
28
EUROFINS BIOPHARMA PRODUCT TESTING
Hungary
1
$561.48
FRESENIUS KABI ONCOL…
Injection
29
THE ESSES PHARMACY (PRIVATE)
Sri Lanka
1
$481.09
GETWELL PHARMA INDIA…
Injection
30
NIKHIL PHARMA PVT LTD
Nepal
2
$477.96
UNITED BIOTECH PVT LTD
Injection
31
DALIAN CHAOHONGSUPPLY CHAIN MANAGEM
China
1
$465.43
JMB PHARMACEUTICALS …
Injection
32
PHARMACHEIME LTD
Malawi
3
$412.13
MATHI ASSOCIATES
Injection, Tablet
33
AS PER INVOICE POLAND
Poland
1
$397.75
VAMA LIFECARE PVT LTD
Capsule
34
ATLAS TRADING COMPANY
Iraq
1
$386.80
VATS INDUSTRIES PVT …
35
CLYZ PHARMA SARL
Cameroon
1
$254.98
RUN MEDWAY
Injection
36
HOPITAL CARAMED CLINIQUE DU CANCE
Haiti
1
$186.58
DOSSMEGT PHARMACEUTI…
Injection
37
RADEEP SERVICES
Singapore
1
$184.98
PHARMA CHOICE LLP
Injection
38
R P L
South Africa
1
$167.89
VENUS REMEDIES LTD
Injection
39
AUTOMOBILE TRANSPORTATION SERVICES
Lebanon
1
$165.80
TRIKAYA GLOBAL
Capsule
40
MINISTRY OF HEALTH ( CLAUDE JULIEN
Seychelles
1
$165.68
SAYAR LIFE-CARE
Vial
41
ACCORD HEALTHCARE SM SA
Greece
3
$157.99
INTAS PHARMACEUTICAL…
Injection
42
DISTRIBUIDORA MEDICA PAREDES S.DE
Mexico
2
$149.83
ATLAS ENTERPRISES
43
OUMAR KONE
Mali
1
$134.40
KHATU ENTERPRISES
Injection
44
PH.EBENA
Cote d'Ivoire
1
$107.91
SAMEEKSHA PHARMACEUT…
Injection
45
A.SAS
Colombia
1
$96.71
VENUS REMEDIES LTD
Injection
46
STATE TRADING ORGANIZATION PLC
Maldives
1
$70.29
MC PHARMA DISTRIBUTORS
Capsule
47
MEDIMART DRUG STORE
United Arab Emirates
1
$54.85
DROPS PHARMA PVT LTD
Injection
48
ROYAL PHARMA COMPANY
Egypt
1
$44.87
AL-ROYAL PHARMACEUTI…
Capsule
49
AS PER INVOICE GHANA
Ghana
2
$27.59
VAMA HEALTH WORLD LLP
Injection, Capsule
50
MOHAMED AHEMED MOHAMUD
Somalia
1
$9.00
M T MADON EXPORTS
Injection
51
DISTRIBUIDORA MEDICA PAREDES S.DE R
Mexico
1
$6.83
ATLAS ENTERPRISES
Injection
52
HANITRA RAZAOARIMANANA
Madagascar
1
$0.865
GETWELL PHARMA INDIA…
Injection
53
HEALTH CITY CAYMAN ISLANDS (HCCI)
Cayman Islands
1
$0.837
NARAYANA HRUDAYALAYA…
Injection
54
SUNCREST INTERNATIONAL LTD
Trinidad and Tobago
1
$0.499
GETWELL PHARMA INDIA…
Injection
55
SESAGO HEALTHCARE LTD
Papua New Guinea
1
$0.0000
ARIHANT EXPORTERS
Injection
This report covers 258 2025-Q4 Etoposide shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/etoposide
Talk to our trade analyst
Need a custom etoposide report or a deeper dive into any market? Our team is ready.